HLA-A*0301 KRAS G12V Complex 蛋白, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi)

HLA-A*0301 collaborates with B2M to present viral and tumor peptides, guiding CD8-positive T cell responses against infected or transformed cells. It can also present self-peptides, avoiding autoreactivity. The antigen recognition specificity involves the peptide and MHC residues, with HLA-A*0301 presenting 8 to 13 amino acid peptides, characterized by allele-specific binding motifs. Specific alleles, like A*01:01 and A*03:01, present a distinct repertoire of peptides, including viral and tumor epitopes. HLA-A*0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi) is a recombinant protein dimer complex containing HLA-A*0301 and B2M/Beta-2-microglobulin Protein, expressed by HEK293 , with C-Avi, C-His labeled tag and VVGAVGVGK peptide. HLA-A*0301 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi), has molecular weight of 52-60 kDa.

HLA-A*0301 是一种关键的抗原呈递主要组织相容性复合物 I 类 (MHCI) 分子，与 B2M/β2 微球蛋白合作，主要在抗原呈递细胞上展示病毒和肿瘤衍生肽。这种呈现允许 HLA-A 限制性 CD8 阳性 T 细胞上的 α-β T 细胞受体 (TCR) 识别，从而引导抗原特异性 T 细胞免疫反应以消除感染或转化的细胞。此外，HLA-A*0301 可能呈递源自分泌蛋白或膜蛋白的信号序列的自身肽，尽管对这些肽具有特异性的 T 细胞通常会被灭活以防止自身反应。 TCR 对肽和 MHC 分子的识别强调了抗原识别的精细特异性，肽负责这种特异性，MHC 残基负责 T 细胞的 MHC 限制。 HLA-A*0301 通常呈递 8 至 13 个氨基酸的细胞内肽抗原，该抗原是通过 IFNG 诱导的免疫蛋白酶体或通过内肽酶 IDE/胰岛素降解酶进行胞质蛋白水解而产生的。它可以结合含有主要由位置 2 和 9 处的锚定残基定义的等位基因特异性结合基序的不同肽。值得注意的是，特定等位基因，例如 A*01:01 和 A*03:01，呈现出有限的肽库，包括病毒肽和肿瘤表位，每个表位都有不同的基序和锚点。

Human

HEK293

C-Avi;C-His

NP_002107.3 (G25-T305)&P61769 (I21-M119)&VVGAVGVGK

3105&567

52-60 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.